Lundbeck epilepsy drug receives FDA approval
Lundbeck Inc has received approval from the FDA for its two New Drug Applications (NDA), Sabril (vigabatrin) Tablets and Oral Solution. Lundbeck will be launching Sabril in the US during the third quarter. Sabril is indicated as a monotherapy for pediatric patients, aged between one month and two years, with infantile spasms for whom the potential benefits outweigh the potential risk of vision loss. The drug is also indicated as an add-on therapy for adult patients with refractory complex partial seizures who have failed other available treatments and for whom the potential benefits outweigh the risk of vision loss.
- Ranbaxy receives provisional FDA nod for generic Nexium
- Abbott receives FDA approval for cholesterol drug
- Roxane Receives FDA Approval For Anastrozole Tablets
- Spiration, Inc’s IBV® Valve System receives HDE approval from FDA
